BioDelivery Sciences ‘pleased’ with mixed ruling over Opioid drug claims

21-12-2021

Alex Baldwin

BioDelivery Sciences ‘pleased’ with mixed ruling over Opioid drug claims

Pavel Kapysh / Shutterstock.com

A Delaware Federal Court has upheld some of the validity of challenged claims in two patents related to BioDelivery Sciences’ (BDSI) opioid medication Belbuca (buprenorphine), but invalidated others.


BioDelivery Sciences, Belbuca, US District Court for the District of Delaware

LSIPR